Related Experiment Videos
Solid phase library synthesis of cyclic depsipeptides: aurilide and aurilide analogues
Takashi Takahashi1, Hiroyuki Nagamiya, Takayuki Doi
1Department of Applied Chemistry, 2-12-1 Ookayama, Meguro, Tokyo 152-8552, Japan. ttakashi@o.cc.titech.ac.jp
Journal of Combinatorial Chemistry
|July 15, 2003
Summary
Researchers developed a solid-phase synthesis for cyclic depsipeptide aurilide and analogues. This method enables efficient combinatorial library generation for drug discovery.
Area of Science:
- Organic Chemistry
- Medicinal Chemistry
- Synthetic Chemistry
Background:
- Cyclic depsipeptides like aurilide are complex natural products with potential biological activities.
- Developing efficient synthetic routes is crucial for accessing these compounds and their analogues for further study.
Purpose of the Study:
- To describe a solid-phase combinatorial synthesis approach for aurilide and related analogues.
- To establish an optimized and efficient method for generating a library of aurilide derivatives.
Main Methods:
- Solid-phase synthesis utilizing trityl linker-functionalized SynPhase Crowns and Fmoc strategy for peptide assembly.
- Optimization of tetrapeptide assembly via parallel synthesis and liquid chromatography-mass spectrometry (LC/MS) analysis.
- Coupling of aliphatic moiety to solid-supported peptide, followed by deprotection, cleavage, and macrocyclization under high dilution conditions.
Main Results:
- Aurilide (1) was synthesized in 11% overall yield after deprotection and macrocyclization.
- A combinatorial library of aurilide derivatives (4) was successfully synthesized using a similar protocol and the TranSort technique.
- The described method provides a viable route for generating diverse cyclic depsipeptide analogues.
Conclusions:
- The developed solid-phase combinatorial synthesis is effective for producing aurilide and its analogues.
- This approach facilitates the generation of compound libraries for exploring structure-activity relationships.
- The methodology offers a platform for discovering novel cyclic depsipeptide-based therapeutics.